- Nirvana Life Sciences (NIRV) announced the appointment of Sheldon Inwentash to the company’s Board of Directors
- Inwentash is founder, chairman and Chief Executive Officer of ThreeD Capital
- He is a veteran entrepreneur with more than 30 years of successful investing experience
- Nirvana focuses on developing medical products and regimens that address addiction
- Nirvana Life Sciences Inc. (NIRV) opened trading at C$0.20 per share
Nirvana Life Sciences (NIRV) has appointed Sheldon Inwentash to the company’s Board of Directors.
Inwentash is founder, chairman and Chief Executive Officer of ThreeD Capital Inc. He is a veteran entrepreneur with more than 30 years of successful investing experience. He has an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests.
Inwentash founded ThreeD Capital to provide unique investment opportunities in several areas. Specifically early stage small cap stock, resource and disruptive technologies.
Inwentash graduated from the University of Toronto with a B.Comm degree. He was later awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur and philanthropist and his dedication to youth.
Bruce Clark, CEO of Nirvana, commented on the appointment.
“We are pleased that Mr. Inwentash has chosen to join our Board. He brings a clear understanding of the value that alternative therapies can play in the treatment of addiction and the management of chronic pain. His experience with disruptive technologies will be impactful as we move to the next phase of our development”.
Nirvana focuses on developing medical products and regimens that address addiction. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency and other health problems.
Nirvana Life Sciences Inc. (NIRV) opened trading at C$0.20 per share.
